[go: up one dir, main page]

DE69516403T2 - Photodynamische konjugate mit biozide eigenschaften - Google Patents

Photodynamische konjugate mit biozide eigenschaften

Info

Publication number
DE69516403T2
DE69516403T2 DE69516403T DE69516403T DE69516403T2 DE 69516403 T2 DE69516403 T2 DE 69516403T2 DE 69516403 T DE69516403 T DE 69516403T DE 69516403 T DE69516403 T DE 69516403T DE 69516403 T2 DE69516403 T2 DE 69516403T2
Authority
DE
Germany
Prior art keywords
methyl
terthien
formula
compound
αtposu
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69516403T
Other languages
English (en)
Other versions
DE69516403D1 (de
Inventor
Giovanni Neri
Gabrio Roncucci
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Molteni and C SpA
Original Assignee
Molteni and C SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Molteni and C SpA filed Critical Molteni and C SpA
Publication of DE69516403D1 publication Critical patent/DE69516403D1/de
Application granted granted Critical
Publication of DE69516403T2 publication Critical patent/DE69516403T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
    • C07D333/14—Radicals substituted by singly bound hetero atoms other than halogen
    • C07D333/20—Radicals substituted by singly bound hetero atoms other than halogen by nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
    • C07D333/22—Radicals substituted by doubly bound hetero atoms, or by two hetero atoms other than halogen singly bound to the same carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
    • C07D333/24—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Claims (16)

1. Konjugate bestehend aus einem Trägermolekül und einem organischen Molekül, das Singulett-Sauerstoff nach Bestrahlung effizient herstellen kann, wobei das organische Molekül, das Singulett-Sauerstoff nach Bestrahlung effizient herstellen kann, eine Verbindung mit der Formel (I)
ist, worin Z&sub1;, Z&sub1; und Z&sub3; gleich oder verschieden voneinander S oder O sind, die entsprechend derivatisiert sind, um mit einer Amino-, Thio-, Saccharid-, Histidin- oder Thyrosingruppe des Trägermoleküls zu reagieren, und das Trägermolekül ist ausgewählt aus Antikörpern, Peptiden, Haptameren, Zuckern oder anderen analogen Trägern, die das Fotosensibilisatormolekül in Richtung des biologischen Ziels dirigieren können.
2. Konjugate gemäß Anspruch 1, wobei die Verbindung der Formel (I) ein 2,2' : 5',2"-Terthiophen ist, das entsprechend derivatisiert ist, um mit einer Amino-, Thio-, Saccharid-, Histidin- oder Tyrosingruppe des Trägermoleküls zu reagieren, sowie an Biotin und fotoreaktiven Seitenketten gebunden sein kann.
3. Konjugate gemäß Anspruch 1, wobei das Trägermolekül an das α-T durch einen Avidin-Biotin-Komplex gebunden ist.
4. Konjugate gemäß Anspruch 1, worin die Verbindung mit der Formel (I) so derivatisiert ist, um mit einer Aminogruppe des Trägermoleküls zu reagieren.
5. Verbindungen der Formel (I) gemäß Anspruch 4 dargestellt durch die folgenden Formeln:
(E) -3-(2,2' : 5',2"-Terthien-5-yl)propen-N-hydroxysuccinimidester N-(5-methyl-2,2' : 5',2"-terthien-5-yl)-1-prolin-N-hydroxysuccinimidester [α-TPOSu]
N-methyl-N-(5-methyl-2,2' : 5',2"-terthien-5-yl)glycin-N-hydroxysuccinimidester
N-methyl-N-(5-methyl-2,2' : 5',2"-terthien-5-yl)glycin-N-hydroxysulfosuccinimidester
N-5-Methyl-(2,2' : 5',2"-terthien-5-yl)-1-prolin-N-hydroxysulfosuccinimidester
N-Methyl-N-5-methyl-(2,2' : 5',2"-terthien-5-yl)monomethylsuccinimidatamid-hydrochlorid
N-Methyl-N-5-methyl-(2,2' : 5',2"-terthien-5-yl)-3-p-azidophenylpropanamid
N-Methyl-N-5-methyl-(2,2' : 5',2"-terthien-5-yl)-3-(2'-nitro-5'-azido)- phenylpropanamid.
6. Konjugate gemäß Anspruch 1, wobei die Verbindung der Formel (I) so derivatisiert ist, um mit einer Thiolgruppe des Trägermoleküls zu reagieren.
7. Verbindungen der Formel (I) gemäß Anspruch 6, dargestellt durch die folgenden Formeln:
N-Methyl-N-(5-methyl-2,2' : 5',2"-terthien-5-yl)-bromacetamid
S,S-Pyridyl-dithio-N-methyl-(5-methyl-(2,2' : 5',2"-terthien-5-yl)- propanamid
N-Methyl-N-5-methyl-(2,2 : 5',2"-terthien-5-yl)-4-(N-maleimidmethyl)- cyclohexyl-1-carboxyamid.
8. Konjugate gemäß Anspruch 1, wobei die Verbindung der Formel (I) so derivatisiert ist, um mit einer Saccharidgruppe des Trägermoleküls zu reagieren.
9. Verbindungen der Formel (I) gemäß Anspruch 8 dargestellt durch:
N-αMethyl-Nα-5-methyl-(2,2' : 5',2"-terthien-5-yl)glycylhydrazid.
10. Konjugate gemäß Anspruch 1, wobei die Verbindung der Formel (I) so derivatisiert ist, daß sie mit einer Histidin- oder Thyrosingruppe reagieren kann.
11. Verbindung der Formel (I) gemäß Anspruch 10 dargestellt durch:
N-Methyl-N-5-methyl-(2,2' : 5',2"-terthien-5-yl)-p-aminobenzamid.
12. Konjugate gemäß Anspruch 1, worin die Verbindung der Formel (I) so derivatisiert ist, daß sie mit Biotin reagieren kann.
13. Verbindung der Formel (I) gemäß Anspruch 12 dargestellt durch:
N,N'-Dimethyl-N-5-methyl-(2,2' : 5',2"-terthien-5-yl)-N-biotinyl-1,2- diaminoethan
N-Methyl-N-(2,2' : 5',2"-terthien-5-yl)methyl-biotinamid.
14. Konjugate gemäß Anspruch 1 erhalten durch Konjugieren von:
αTPOSu und Concanavalin A
αTPOSu und Succinyl-Concanavalin A
αTPOSu und Avidin
(α-T)-CHO und BSA
αTPOSu und monoklonalem Antikörper 225-28S
(α-T)-BrAc und scFv-cys
αTPOSu und monoklonalem Antikörper anti C. albicans
αTPOSu und monoklonalem Antikörper anti Herpes simplex Virus 1 und 2
αTPOSu und humanem monoklonalem Antikörper anti Herpes simplex Virus 1 und 2 Fab Fragment
αTPOSu und monoklonalem Antikörper anti Rubella Virus.
15. Verwendung der Konjugate gemäß Anspruch 1 zur Herstellung von antibakteriellen, antiviralen, antifungiziden und Antitumor-Zusammensetzungen in Kombination mit geeigneten pharmazeutisch annehmbaren Exzipienten.
16. Verwendung gemäß Anspruch 15, wobei die Zusammensetzungen zur oralen, intramuskulären und topischen Verwendung sind.
DE69516403T 1994-05-23 1995-05-22 Photodynamische konjugate mit biozide eigenschaften Expired - Fee Related DE69516403T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IT94FI000095A ITFI940095A1 (it) 1994-05-23 1994-05-23 Coniugati fotodinamici aventi proprieta' biocide
PCT/EP1995/001938 WO1995032001A1 (en) 1994-05-23 1995-05-22 Photodynamic conjugates with biocidal properties

Publications (2)

Publication Number Publication Date
DE69516403D1 DE69516403D1 (de) 2000-05-25
DE69516403T2 true DE69516403T2 (de) 2000-11-23

Family

ID=11350877

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69516403T Expired - Fee Related DE69516403T2 (de) 1994-05-23 1995-05-22 Photodynamische konjugate mit biozide eigenschaften

Country Status (9)

Country Link
US (1) US5869051A (de)
EP (1) EP0760679B1 (de)
AT (1) ATE191852T1 (de)
AU (1) AU2566295A (de)
CA (1) CA2191195A1 (de)
DE (1) DE69516403T2 (de)
ES (1) ES2147288T3 (de)
IT (1) ITFI940095A1 (de)
WO (1) WO1995032001A1 (de)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2066552C1 (ru) * 1996-02-12 1996-09-20 Товарищество с ограниченной ответственностью "Био Прогресс" Композиция для фотодинамического повреждения клеток-мишеней и способ фотодинамического повреждения клеток-мишеней
GB9610967D0 (en) 1996-05-24 1996-07-31 Cambridge Antibody Tech Specific binding members,materials and methods
ATE409005T1 (de) * 1997-03-19 2008-10-15 Lucid Inc Zellchirurgie unter benutzung konfokaler mikroskopie
US5994394A (en) * 1997-03-21 1999-11-30 Industrial Technology Research Institute Polyheterocyclic compounds
CA2356532A1 (en) 1999-01-15 2000-07-20 Light Sciences Corporation Noninvasive vascular therapy
US6602274B1 (en) 1999-01-15 2003-08-05 Light Sciences Corporation Targeted transcutaneous cancer therapy
US6454789B1 (en) 1999-01-15 2002-09-24 Light Science Corporation Patient portable device for photodynamic therapy
US20030114434A1 (en) * 1999-08-31 2003-06-19 James Chen Extended duration light activated cancer therapy
EP1267935A2 (de) 2000-01-12 2003-01-02 Light Sciences Corporation Behandlung von augenerkrankungen
EP1259548A1 (de) 2000-02-24 2002-11-27 Eidgenössische Technische Hochschule Zürich Antikörper gegen die ed-b domäne von fibronektin, konjugate die diesen antikörper enthalten, und deren verwendung zum nachweis und zur behandlung von angiogenese
ITBA20000020A1 (it) * 2000-05-31 2001-12-01 Giovanna Barbarella Oligomeri del tiofene come marcatori fluorescenti ad alta efficienza per il riconoscimento e l'analisi quantitativa di molecole biologiche.
WO2003024954A1 (en) * 2001-09-12 2003-03-27 Pusan National University Industry-University Cooperation Foundation Novel terthiophene-3-carboxylic acid compound and fabricating method thereof, functionalized conductive terthiophene polymer with the compound as a monomer, process for dna hybridizatioon detection using the polymer, and fabricating method of probe dna
ITBO20040697A1 (it) * 2004-11-11 2005-02-11 Consiglio Nazionale Ricerche Sonde oligonucleotidiche
WO2011073054A1 (en) * 2009-12-15 2011-06-23 Centre National De La Recherche Scientifique Biphotonic photosensitizers, nanoparticles containing the same and their use as drugs
CN103201279A (zh) 2010-11-05 2013-07-10 赛诺米克斯公司 作为trpm8的调节剂有用的化合物
MX389514B (es) 2015-10-01 2025-03-20 Firmenich Incorporated Compuestos útiles como moduladores de canal receptor 8 de potencial transitorio de melastatina (trpm8).

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1173743A (en) * 1981-11-27 1984-09-04 George H.N. Towers Method for controlling pests using a naturally occurring conjugated polyacetylene
US4920143A (en) * 1987-04-23 1990-04-24 University Of British Columbia Hydro-monobenzoporphyrin wavelength-specific cytotoxic agents
EP0454204B1 (de) * 1990-04-27 1995-06-28 Duphar International Research B.V Verfahren zur photochemischen Isomerisierung von organischen Verbindungen unter dem Einfluss eines Photosensibilisators

Also Published As

Publication number Publication date
ITFI940095A1 (it) 1995-11-23
DE69516403D1 (de) 2000-05-25
US5869051A (en) 1999-02-09
ITFI940095A0 (it) 1994-05-23
ATE191852T1 (de) 2000-05-15
CA2191195A1 (en) 1995-11-30
ES2147288T3 (es) 2000-09-01
AU2566295A (en) 1995-12-18
WO1995032001A1 (en) 1995-11-30
EP0760679A1 (de) 1997-03-12
EP0760679B1 (de) 2000-04-19

Similar Documents

Publication Publication Date Title
DE69516403T2 (de) Photodynamische konjugate mit biozide eigenschaften
DE68914457T2 (de) Gereinigte hematoporphyrin trimere zur verwendung bei photodynamischer therapie.
DE3588090T2 (de) Durch Säuren spaltbare Verbindungen
DE68912232T2 (de) Konjugate zytotoxischer Arzneimittel.
DE3686683T2 (de) Tetrapyrrolpolyaminomonocarbonsaeure-therapiemittel.
DE3587579T2 (de) Pharmazeutische Zubereitung enthaltend eine Tetrahydropyrrolverbindung als aktiven Bestandteil und Verfahren zur Herstellung dieser Tetrapyrrolverbindung.
DE3878866T2 (de) 3-indolpyruvsaeure-derivate und deren verwendung als arznemittel.
DE69813570T2 (de) 5-alkyl-2-arylaminophenylessigsäure und derivative
DE3031164C2 (de) Angelicine enthaltende Arzneimittel, Angelicine als solche sowie Verfahren zu deren Herstellung
DE60319406T2 (de) Meso-substituierte porphyrine
DE60125555T2 (de) 5-aminolaevulinsäure-ester als mittel zur photosensibilisierung in der chemotherapie
DE69426629T2 (de) Therapeutische verbindung - fettsäurekonjugate
DE60204767T2 (de) Metallsubstituierte, nicht zentrosymmetrische phthalocyanin-analoga, deren herstellung und verwendung zur photodynamischen therapie, und als in-vivo-diagnostikum
DE60023748T2 (de) Chlorophyll- und bacteriochlorophyllester, deren herstellung und diese enthaltende pharmazeutische zusammensetzungen
DD204849A5 (de) Verfahren zur herstellung von produkten fuer die behandlung von melanomen
DE68927610T2 (de) Antikörper-Arzneimittel Konjugale
DE112018007259T5 (de) Antikörper-Wirkstoff-Konjugat mit einer säurebildenden Selbststabilisierungs-Anbindung
DE60008354T2 (de) Substituierte Metallphthalocyaninen, ihre Herstellung und Verwendung
WO2007144200A1 (de) Verfahren zur kovalenten verknüpfung zweier moleküle mittels diels-alder-reaktion mit inversem elektronenbedarf
DE3129750A1 (de) 5'-aminoalkyl-4',4,8-trialkylpsoralene
DE3205655C2 (de)
EP0819135A1 (de) Kohlenhydratmodifizierte cytostatika
DE69805334T2 (de) Derivate des vitamin e
DE3033895C2 (de)
DE68910211T2 (de) Estramustin-ester.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee